Close Menu

NEW YORK – Lucid Diagnostics, a PAVmed subsidiary, said Thursday that it has received breakthrough device designation from the US Food and Drug Administration for a test to detect esophageal dysplasia and potential cancer risk.

Called the EsoGuard Esophageal DNA Test, the assay is meant to be performed on esophageal samples collected using the firm's EsoCheck Cell Collection Device in a well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease, or GERD.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.